spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Spectrum OR 

 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2015
Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA(TM) (melphalan) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 5 Jun 2013
Spectrum Pharmaceuticals Further Strengthens Management; Announces Appointment of Kurt Gustafson as Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2013
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Jan 2013
Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2012
Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2012
Spectrum Pharmaceuticals Appoints Industry Veteran, Former Amgen Executive Joseph Turgeon, as Senior Vice President Sales & Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Sep 2012
Spectrum Pharmaceuticals Appoints Industry Veteran and Former Senior Amgen Executive, Ken Keller, as Executive Vice President, Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2012
Spectrum Pharmaceuticals Launches a Broad-based FUSILEV(R) Marketing Campaign; Increases Sales Force Footprint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2012
Spectrum Pharmaceuticals Strengthens Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Spectrum Pharmaceuticals to Develop Biosimilar Rituximab
Biopharmaceuticals Oncology Generics
 HSMN NewsFeed - 12 Oct 2010
Spectrum Pharmaceuticals Announces Appointment of Brett L. Scott as Senior Vice President and Acting Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jul 2010
Spectrum Pharmaceuticals Appoints George Tidmarsh, M.D., Ph.D, as Senior Vice President, Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jun 2010
Spectrum Pharmaceuticals Appoints James E. Shields as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2010
Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV(R) sNDA under Review for Advanced Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 8 Oct 2009
Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Jul 2009
FDA Designates Fast Track Status for Apaziquone (EOquin(R)) for Bladder Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 31 Oct 2008
Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2008
Spectrum Pharmaceuticals Launches FUSILEV(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2008
Mindray's AS3000(TM) Anesthesia Delivery System Receives U.S. FDA Clearance
Devices FDA
 HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 May 2008
Spectrum Pharmaceuticals Announces Sale of Injectable Generic Drugs to Sagent Pharmaceuticals, Inc.
Biopharmaceuticals Generics
 HSMN NewsFeed - 7 May 2008
Spectrum Pharmaceuticals Receives $20 Million Cash Payment from Par Pharmaceutical for Sumatriptan Injection
Biopharmaceuticals
 HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Feb 2008
Oculus Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn(R) Technology in Mildly Infected Diabetic Foot Ulcers
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 19 Feb 2008
Spectrum Pharmaceuticals Receives Approval from Canadian Authorities to Expand EOquin(R) Registrational, Phase 3 Clinical Trials into Canada
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2008
Spectrum Pharmaceuticals Strengthens Management; Appoints Oncologist Richard A. Bender, MD as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
Oculus Innovative Sciences Completes Patient Treatment and Follow-up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 6 Nov 2007
Spectrum Pharmaceuticals Announces Arbitration Panel Ruling
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 31 Oct 2007
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
Spectrum Pharmaceuticals Investigational New Drug Application for SPI-1620 Cleared by U.S. Food & Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jul 2007
Marketing Authorization Application for Satraplatin Accepted for Review by the European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jul 2007
Spectrum Pharmaceuticals Acquires From Indena Worldwide Rights To Ortataxel, A Phase 2 Third Generation Taxane
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Jul 2007
Spectrum Strengthens Management With the Appointment of George Uy, an Industry Veteran, as Vice President, Marketing Oncology/Urology
Biopharmaceuticals Oncology Urology Personnel
 HSMN NewsFeed - 24 May 2007
Datascope Corp. Announces Agreement to Acquire Artema Medical AB
Devices Mergers & Acquisitions
 HSMN NewsFeed - 23 May 2007
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 May 2007
Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 15 May 2007
Spectrum Pharmaceuticals Announces FDA'S Oncology Drug Advisory Committee to Review Satraplatin for the Treatment of Hormone Refractory Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
Spectrum Pharmaceuticals Initiates Phase 3, Registrational Trials With EOquin(R) in Non-Invasive Bladder Cancer
Biopharmaceuticals Drug Delivery Urology Oncology
 HSMN NewsFeed - 16 Apr 2007
FDA Accepts Satraplatin NDA And Grants Priority Review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Mar 2007
Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2007
Spectrum Pharmaceuticals Bolsters Ozarelix Team with Addition of In-House Urology Expert Bela S. Denes, MD, FACS
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 23 Feb 2007
Spectrum Pharmaceuticals Announces Satraplatin Data Presentation at the American Society of Clinical Oncology Prostate Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2007
Spectrum Pharmaceuticals Announces Completion of NDA Filing for Satraplatin for Hormone Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Feb 2007
Datascope Receives FDA Clearance to Include Depth-of-Anesthesia Monitoring in the Spectrum(R) OR Monitor
Devices Monitoring FDA
 HSMN NewsFeed - 25 Jan 2007
Spectrum Pharmaceuticals Initiates Phase 2b Trial for Ozarelix in Patients with Benign Prostate Hypertrophy
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Jan 2007
Spectrum Pharmaceuticals Announces FDA's Acceptance of Ozarelix IND and Approval of Phase 2b Protocol in BPH (Benign Prostate Hypertrophy)
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 Dec 2006
Spectrum Pharmaceuticals Announces That Sumatriptan Injection Litigation With GlaxoSmithKline(R) Has Been Dismissed Pursuant to the Settlement Agreement
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Dec 2006
Spectrum Pharmaceuticals Files Arbitration Claim Against GPC Biotech AG for Violations of Satraplatin License Agreement
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 13 Nov 2006
Spectrum Pharmaceuticals Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Oct 2006
Spectrum Pharmaceuticals Announces Positive Phase 2 Data with Ozarelix in Patients with Benign Prostatic Hypertrophy
Biopharmaceuticals Urology
 HSMN NewsFeed - 24 Sep 2006
Spectrum Pharmaceuticals Announces Positive Results of Satraplatin Pivotal Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2006
Independent Data Monitoring Board Recommends Expedited Interim Analysis of Overall Survival Data for Satraplatin Phase 3 Trial
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 54

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 54 additional stories matching:
Spectrum OR
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.